S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
One company did the impossible with AI (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
One company did the impossible with AI (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
One company did the impossible with AI (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
"Chilling War Games Show US Forces Crushed" – FOX NEWS (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
One company did the impossible with AI (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast

Novo Nordisk A/S (NVO) Competitors

$120.93
-0.52 (-0.43%)
(As of 02/21/2024 ET)

NVO vs. JNJ, LLY, MRK, ABBV, NVS, AZN, ABT, PFE, UNH, and TMO

Should you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novartis (NVS), AstraZeneca (AZN), Abbott Laboratories (ABT), Pfizer (PFE), UnitedHealth Group (UNH), and Thermo Fisher Scientific (TMO). These companies are all part of the "medical" sector.

Novo Nordisk A/S vs.

Novo Nordisk A/S (NYSE:NVO) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.

Johnson & Johnson has a net margin of 37.79% compared to Novo Nordisk A/S's net margin of 36.03%. Novo Nordisk A/S's return on equity of 90.36% beat Johnson & Johnson's return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S36.03% 90.36% 29.18%
Johnson & Johnson 37.79%37.27%14.84%

Novo Nordisk A/S currently has a consensus price target of $121.25, suggesting a potential upside of 0.26%. Johnson & Johnson has a consensus price target of $176.14, suggesting a potential upside of 11.01%. Given Johnson & Johnson's higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Novo Nordisk A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Johnson & Johnson
0 Sell rating(s)
8 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38

In the previous week, Johnson & Johnson had 2 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 39 mentions for Johnson & Johnson and 37 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 0.84 beat Johnson & Johnson's score of 0.74 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
21 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Johnson & Johnson
26 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive

Novo Nordisk A/S has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.

Johnson & Johnson received 678 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. Likewise, 64.88% of users gave Johnson & Johnson an outperform vote while only 60.36% of users gave Novo Nordisk A/S an outperform vote.

CompanyUnderperformOutperform
Novo Nordisk A/SOutperform Votes
399
60.36%
Underperform Votes
262
39.64%
Johnson & JohnsonOutperform Votes
1077
64.88%
Underperform Votes
583
35.12%

6.4% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 68.4% of Johnson & Johnson shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Johnson & Johnson is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$33.71B16.10$12.15B$2.7144.71
Johnson & Johnson$85.16B4.49$35.15B$13.8111.49

Novo Nordisk A/S pays an annual dividend of $0.62 per share and has a dividend yield of 0.5%. Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 3.0%. Novo Nordisk A/S pays out 22.9% of its earnings in the form of a dividend. Johnson & Johnson pays out 34.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Johnson & Johnson beats Novo Nordisk A/S on 12 of the 20 factors compared between the two stocks.


Get Novo Nordisk A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVO vs. The Competition

MetricNovo Nordisk A/SPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$545.01B$6.65B$4.97B$17.20B
Dividend Yield0.51%2.74%2.91%3.56%
P/E Ratio44.719.2495.3021.35
Price / Sales16.10796.443,262.615.67
Price / Cash40.3418.3289.1417.92
Price / Book35.054.414.286.24
Net Income$12.15B$156.18M$112.46M$869.26M
7 Day Performance-0.65%-0.01%0.71%-1.23%
1 Month Performance14.64%8.75%5.96%1.52%
1 Year Performance240.05%-0.44%7.25%76.11%

Novo Nordisk A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JNJ
Johnson & Johnson
4.9682 of 5 stars
$156.55
-0.1%
$176.14
+12.5%
+0.4%$376.86B$85.16B11.34155,800Analyst Report
LLY
Eli Lilly and Company
4.8878 of 5 stars
$782.06
+3.2%
$655.50
-16.2%
+127.7%$742.42B$34.12B134.8439,000Analyst Report
Gap Down
MRK
Merck & Co., Inc.
4.7341 of 5 stars
$127.79
+1.0%
$129.68
+1.5%
+17.5%$323.82B$60.12B912.7969,000Analyst Revision
ABBV
AbbVie
4.7955 of 5 stars
$177.49
+0.5%
$175.36
-1.2%
+15.2%$319.48B$54.32B65.0150,000Dividend Announcement
Analyst Revision
NVS
Novartis
2.2948 of 5 stars
$100.19
+0.6%
$99.50
-0.7%
+18.2%$212.36B$45.44B13.9576,057Analyst Revision
Gap Up
AZN
AstraZeneca
3.8753 of 5 stars
$64.27
+2.3%
$80.00
+24.5%
-6.5%$199.26B$45.81B33.4783,500Gap Up
ABT
Abbott Laboratories
4.887 of 5 stars
$114.01
+0.3%
$120.00
+5.3%
+13.7%$197.93B$40.11B34.97115,000Dividend Announcement
PFE
Pfizer
4.9984 of 5 stars
$27.62
+0.4%
$36.93
+33.7%
-35.2%$155.95B$58.50B76.7283,000
UNH
UnitedHealth Group
4.9785 of 5 stars
$521.55
+0.1%
$575.79
+10.4%
+6.2%$482.39B$371.62B21.88400,000Positive News
TMO
Thermo Fisher Scientific
4.8193 of 5 stars
$547.84
-0.1%
$596.00
+8.8%
+0.4%$211.67B$42.86B35.46130,000Dividend Increase
Insider Selling

Related Companies and Tools

This page (NYSE:NVO) was last updated on 2/22/2024 by MarketBeat.com Staff